Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience
Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in critically ill patients, particularly in those with sepsis and septic shock. We assessed the effect of therapeutic dr...
Gespeichert in:
Veröffentlicht in: | Infection 2019-12, Vol.47 (6), p.1001-1011 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
Standard dosing and intermittent bolus application (IB) are important risk factors for pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in critically ill patients, particularly in those with sepsis and septic shock. We assessed the effect of therapeutic drug monitoring-guided (TDM), continuous infusion (CI) and individual dosing of piperacillin/tazobactam (PIP) on PK-target attainment in critically ill patients.
Methods
This is a retrospective, single-center analysis of a database including 484 patients [933 serum concentrations (SC)] with severe infections, sepsis and septic shock who received TDM-guided CI of PIP in the intensive care unit (ICU) of an academic teaching hospital. The PK-target was defined as a PIP SC between 33 and 64 mg/L [
f
T > 2–4 times the epidemiological cutoff value (ECOFF) of
Pseudomonas aeruginosa
(PSA)].
Results
PK-target attainment with standard dosing (initial dose) was observed in 166 patients (34.3%), whereas only 49 patients (10.1%) demonstrated target non-attainment. The minimum PK-target of ≥ 33 mg/L was overall realized in 89.9% (
n
= 435/484) of patients after the first PIP dose including 146 patients (30.2%) with potentially harmful SCs ≥ 100 mg/L. Subsequent TDM-guided dose adjustments significantly enhanced PK-target attainment to 280 patients (62.4%) and significantly reduced the fraction of potentially overdosed (≥ 100 mg/L) patients to 4.5% (
n
= 20/449). Renal replacement therapy (RRT) resulted in a relevant reduction of PIP clearance (CL
PIP
): no RRT CL
PIP
6.8/6.3 L/h (median/IQR) [SCs
n
= 752, patients
n
= 405], continuous veno-venous hemodialysis (CVVHD) CL
PIP
4.3/2.6 L/h [SCs
n
= 160,
n
= 71 patients], intermittent hemodialysis (iHD) CL
PIP
2.6/2.3 L/h [SCs
n
= 21,
n
= 8 patients]). A body mass index (BMI) of > 40 kg/m
2
significantly increased CL
PIP
9.6/7.7 L/h [SC
n
= 43,
n
= 18 patients] in these patients. Age was significantly associated with supratherapeutic PIP concentrations (
p
|
---|---|
ISSN: | 0300-8126 1439-0973 |
DOI: | 10.1007/s15010-019-01352-z |